Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Complement activation by antibodies bound to pathogens, tumors, and self antigens is a
critical feature of natural immune defense, a number of disease processes, and …

Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

CD38, a type II transmembrane glycoprotein highly expressed in hematological
malignancies including multiple myeloma (MM), represents a promising target for mAb …

Objective To assess dose-response effects of the anti-CD20 monoclonal antibody
ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing …

Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or
who have comorbidities is challenging because fludarabine-based chemoimmunotherapies …

Antibody dependent cellular cytotoxicity (ADCC) is an Fc-dependent effector function of IgG
important for anti-viral immunity and anti-tumor therapies. NK-cell mediated ADCC is mainly …

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …